KIT (CD117)-positive breast cancers are infrequent and lack KIT gene mutations.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Clinical Cancer Research

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S0344-0338(04)80597-1PMID 14734467
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Expression of stem-cell factor and its receptor c-kit protein in normal testicular tissue and malignant germ-cell tumours

  2005cited by this paper
• Preferential localization of c-kit product in tissue mast cells, basal cells of skin, epithelial cells of breast, small cell lung carcinoma and seminoma/dysgerminoma in human: immunohistochemical study on formalin-fixed, paraffin-embedded tissues

  2004cited by this paper
• High‐throughput tissue microarray analysis of G1‐cyclin alterations in classical Hodgkin's lymphoma indicates overexpression of cyclin E1

  2003cited by this paper
• Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

  2003cited by this paper
• Conventional and tissue microarray immunohistochemical expression analysis of mismatch repair in hereditary colorectal tumors.

  2003cited by this paper
• Expression of c-kit protein in proliferative lesions of human breast: sexual difference and close association with phosphotyrosine status

  2002influential reference
• Apoptotic rate in peripheral T-cell lymphomas. A study using a tissue microarray with validation on full tissue sections.

  2002cited by this paper
• Clinical significance of molecular expression profiles of Hürthle cell tumors of the thyroid gland analyzed via tissue microarrays.

  2002cited by this paper
• CD117 (KIT): a diverse protein with selective applications in surgical pathology.

  2002cited by this paper
• Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

  2002cited by this paper
• The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations.

  2002cited by this paper
• Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.

  2002cited by this paper
• Application of tissue microarray technology to the study of non-Hodgkin's and Hodgkin's lymphoma.

  2002cited by this paper
• Expert Commentary.

  2002cited by this paper
• Imatinib mesylate (Gleevec, Glivec): a new therapy for chronic myeloid leukemia and other malignancies.

  2002cited by this paper
• Tissue Microarray Sampling Strategy for Prostate Cancer Biomarker Analysis

  2002cited by this paper
• Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers.

  2002cited by this paper
• Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.

  2002cited by this paper
• Evaluation of the tissue microarray technique for immunohistochemical analysis in rectal cancer.

  2002cited by this paper
• Imatinib GIST keeps finding new indications: successful treatment of dermatofibrosarcoma protuberans by targeted inhibition of the platelet-derived growth factor receptor.

  2002cited by this paper
• Response of extraabdominal desmoid tumors to therapy with imatinib mesylate

  2002cited by this paper
• Tissue microarrays for predictive molecular pathology

  2002cited by this paper
• Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution.

  2002cited by this paper
• [Tissue microarray technology--a new and powerful tool for the molecular profiling of tumors].

  2002cited by this paper
• Gastrointestinal stromal tumors with KIT mutations exhibit a remarkably homogeneous gene expression profile.

  2001cited by this paper
• Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.

  2001cited by this paper
• Roots of Clinical Resistance to STI-571 Cancer Therapy

  2001cited by this paper
• Tissue Microarray Technique in Soft Tissue Sarcoma: Immunohistochemical Ki-67 Expression in Malignant Fibrous Histiocytoma

  2001cited by this paper
• Tissue microarrays for rapid linking of molecular changes to clinical endpoints.

  2001cited by this paper
• Tyrosine kinase inhibitor imatinib (STIS71) as an anticancer agent for solid tumours

  2001cited by this paper
• Gastrointestinal Stromal Tumors, Intramural Leiomyomas, and Leiomyosarcomas in the Rectum and Anus: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 144 Cases

  2001cited by this paper
• Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.

  2001cited by this paper
• Imatinib mesylate: clinical results in Philadelphia chromosome-positive leukemias.

  2001cited by this paper
• Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors.

  2001cited by this paper
• STI571: a magic bullet?

  2001cited by this paper
• Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy.

  2001cited by this paper
• High Ki‐67 proliferative index predicts disease specific survival in patients with high‐risk soft tissue sarcomas

  2001cited by this paper
• Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.

  2001cited by this paper
• Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade

  2001cited by this paper
• Expression of the c-kit protein is associated with certain subtypes of salivary gland carcinoma.

  2000cited by this paper
• Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis.

  2000cited by this paper
• Primary small cell (oat cell) carcinoma of the breast: Report of a case and review of the literature

  2000cited by this paper
• Validation of Tissue Microarray Technology in Breast Carcinoma

  2000cited by this paper
• Neuroendocrine expression in metastatic prostate cancer: evaluation of high throughput tissue microarrays to detect heterogeneous protein expression.

  2000cited by this paper
• Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques.

  2000cited by this paper
• KIT protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma.

  1999cited by this paper
• Pathological prognostic factors in breast cancer.

  1999cited by this paper
• High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma.

  1999cited by this paper
• Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays.

  1999cited by this paper
• Tissue microarrays for gene amplification surveys in many different tumor types.

  1999cited by this paper
• Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders.

  1998cited by this paper
• Retroviral Vector Targeting Human Cells via c-Kit–Stem Cell Factor Interaction

  1998cited by this paper
• Sequence analysis of two genomic regions containing the KIT and the FMS receptor tyrosine kinase genes.

  1997cited by this paper
• Immunohistochemical expression of the c-kit proto-oncogene product in human malignant and non-malignant breast tissues.

  1996cited by this paper
• Expression of c-kit and kit ligand proteins in normal human tissues.

  1994cited by this paper
• Expression of the c-kit protein in human solid tumors and in corresponding fetal and adult normal tissues.

  1993cited by this paper
• Expression of c-kit receptor in normal and transformed human nonlymphoid tissues.

  1992cited by this paper
• Breast cancer is associated with loss of the c‐kit oncogene product

  1992cited by this paper
• Progression of human cutaneous melanoma is associated with loss of expression of c‐kit proto‐oncogene receptor

  1992cited by this paper
• pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐up

  1991cited by this paper

• Incorporation of network pharmacology, molecular docking, survival, density functional theory, and experimental studies to explore the potential key targets of formononetin by TERT-mediated anti-cancer effects in MCF-7 breast cancer.

  2026cites this paper
• The carcinogenic capacity of arsenic in normal epithelial breast cells and double-positive breast cancer cells

  2024cites this paper
• Investigating the potential of mono-chalcone compounds in targeting breast cancer receptors through network pharmacology, molecular docking, molecular dynamics simulation, antiproliferative effects, and gene expressions

  2024cites this paper
• Additional prognostic value of polymorphisms within the 3′-untranslated region of programmed cell death pathway genes in early-stage breast cancer

  2024cites this paper
• c-Kit Receptors as a Therapeutic Target in Cancer: Current Insights

  2023cites this paper
• Breast cancer with scalp metastases: a case report

  2023cites this paper
• Lymphoepithelioma-Like Carcinoma of the Breast: A Case Report of a Rare Type of Invasive Carcinoma

  2022cites this paper
• CRISPRa screen identifies a role for c-KIT signaling in tamoxifen resistance, potentially through upregulation of ABC transporters

  2022cites this paper
• Lipid phosphate phosphatase-2 promotes tumor growth through increased c-Myc expression

  2022cites this paper
• Role and significance of c-KIT receptor tyrosine kinase in cancer: A review

  2022cites this paper
• KIT genetic alterations in breast cancer

  2022cites this paper
• New C3H KitN824K/WT cancer mouse model develops late-onset malignant mammary tumors with high penetrance

  2022cites this paper
• Immunohistochemically detectable thyroglobulin expression in extrathyroidal cancer is 100% specific for thyroidal tumor origin.

  2021cites this paper
• c-Kit - The Novel Receptor: Physiological Roles, Downstream Signaling and Implications in Cancer

  2021cites this paper
• Expression of stem cell growth factor receptor CD117 (C-Kit) in breast neoplasms

  2020influential citation
• Homogeneous MMR Deficiency Throughout the Entire Tumor Mass Occurs in a Subset of Colorectal Neuroendocrine Carcinomas

  2020cites this paper
• High homogeneity of MMR deficiency in ovarian cancer.

  2020cites this paper
• MMR deficiency in urothelial carcinoma of the bladder presents with temporal and spatial homogeneity throughout the tumor mass.

  2020cites this paper
• MMR Deficiency is Homogeneous in Pancreatic Carcinoma and Associated with High Density of Cd8-Positive Lymphocytes

  2020cites this paper
• The Relationship between KIT Copy Number Variation, Protein Expression, and Angiogenesis in Sporadic Breast Cancer.

  2020cites this paper
• High homogeneity of mismatch repair deficiency in advanced prostate cancer

  2019cites this paper
• Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus

  2018cites this paper
• Prognostic significance of CD117 expression and TP53 missense mutations in triple-negative breast cancer

  2018cites this paper
• CD 117 Immunoexpression in Invasive Breast Carcinoma: Association with various prognostic parameters

  2018cites this paper
• Loss of c-KIT expression in breast cancer correlates with malignant transformation of breast epithelium and is mediated by KIT gene promoter DNA hypermethylation.

  2018cites this paper
• Estrogen induces c-Kit and an aggressive phenotype in a model of invasive lobular breast cancer

  2017cites this paper
• Node-based differential network analysis in genomics

  2017cites this paper
• Familial Gastrointestinal Stromal Tumor with Germline KIT Mutations Accompanying Hereditary Breast and Ovarian Cancer Syndrome.

  2017cites this paper
• Immunoglobulin superfamily genes are novel prognostic biomarkers for breast cancer

  2016cites this paper
• C-kit and PDGFRA gene mutations in triple negative breast cancer.

  2014cites this paper
• p130Cas alters the differentiation potential of mammary luminal progenitors by deregulating c‐Kit activity

  2013cites this paper
• Biofunctional characteristics of in situ and invasive breast carcinoma

  2013cites this paper
• c‐Kit expression as a prognostic molecular marker in patients with basal‐like breast cancer

  2013cites this paper
• Expression of CD117 in normal and neoplastic breast tissue: the diagnostic significance and correlation with HER-2 neu, estrogen, and progesterone receptors in breast cancer

  2013influential citation
• Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.

  2013cites this paper
• Identification of the c-kit gene mutations in biopsy tissues of mammary gland carcinoma tumor.

  2012cites this paper
• Soluble KIT correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinib

  2012cites this paper
• Screening of the c-kit gene missense mutation in invasive ductal carcinoma of breast among north Indian population

  2012cites this paper
• Targeting basal-like breast cancers.

  2012cites this paper
• Relation of CD117 immunoreactivity and microvascular density in invasive breast carcinoma.

  2012cites this paper
• [Immunohistochemical characteristics of triple negative/basal-like breast cancer].

  2012cites this paper
• Overexpression of c‐KIT (CD117) occurs infrequently in squamous cell carcinoma of the uterine cervix

  2011cites this paper
• Signalling pathways in basal-like breast carcinomas: a clue on pathogenesis and therapeutical targets.

  2011cites this paper
• C-kit expression in pediatric tumors: what is hidden beneath the tip of the iceberg?

  2011cites this paper
• THE IDENTIFICATION AND CHARACTERIZATION OF PROTEIN KINASE INHIBITORS TARGETING BREAST CANCER STEM CELLS

  2011cites this paper
• KIT protein expression and mutational status of KIT gene in pituitary adenomas

  2011cites this paper
• Therapeutic targets in triple negative breast cancer - where are we now?

  2011cites this paper
• Clinicopathological, therapeutic and prognostic features of the triple-negative tumors in moroccan breast cancer patients (experience of Hassan II university hospital in Fez)

  2011cites this paper
• A potential role for targeted therapy in a subset of metastasizing adnexal carcinomas

  2011cites this paper
• Tumorigenesis and Neoplastic Progression An Extensive Tumor Array Analysis Supports Tumor Suppressive Role for Nucleophosmin in Breast Cancer

  2011cites this paper
• Overexpression of c-KIT (CD117) in triple-negative breast cancer

  2011influential citation
• Amplification of 8q21 in breast cancer is independent of MYC and associated with poor patient outcome

  2010cites this paper
• Overexpression of cell division cycle 7 homolog is associated with gene amplification frequency in breast cancer.

  2010cites this paper
• c-kit (CD117) Expression in Human Tumors and its Prognostic Value: An Immunohistochemical Analysis

  2010cites this paper
• Adenoid cystic carcinoma of the breast in the United States (1977 to 2006): a population-based cohort study

  2010cites this paper
• Molecular therapy of breast cancer: progress and future directions

  2010cites this paper
• Clinical Proteomics of Breast Cancer

  2010cites this paper
• Expression of c-kit in Common Benign and Malignant Breast Lesions

  2010cites this paper
• Current data of targeted therapies for the treatment of triple-negative advanced breast cancer: empiricism or evidence-based?

  2009cites this paper
• Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics

  2009cites this paper
• Molecular Classification of Breast Carcinomas by Immunohistochemical Analysis: Are We Ready?

  2009cites this paper
• Quantitative immunohistochemical expression of c Kit in breast carcinomas is predictive of patients' outcome

  2009cites this paper
• What's positive about 'triple-negative' breast cancer?

  2009cites this paper
• Chromosomal changes in aggressive breast cancers with basal-like features.

  2009cites this paper
• Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers

  2009cites this paper
• Triple‐negative/basal‐like breast cancer: review

  2009cites this paper
• Triple negative breast cancers: clinical and prognostic implications.

  2009cites this paper
• Assessment of “grading” with Ki‐67 and c‐kit immunohistochemical expressions may be a helpful tool in management of patients with flat epithelial atypia (FEA) and columnar cell lesions (CCLs) on core breast biopsy

  2009cites this paper
• Silent mutations in KIT and PDGFRA and coexpression of receptors with SCF and PDGFA in Merkel cell carcinoma: implications for tyrosine kinase-based tumorigenesis

  2008cites this paper
• Expression of KIT and PDGFR is associated with a good prognosis in neuroblastoma

  2008cites this paper
• Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations.

  2008cites this paper
• Expression of EGFR and c‐kit is associated with the basal‐like phenotype in breast carcinomas of African women  

  2008influential citation
• CD117 expression in normal, neoplastic, inflammatory, and reactive lesions of the thyroid.

  2008cites this paper
• Basal and triple-negative breast cancers: impact on clinical decision-making and novel therapeutic options.

  2008cites this paper
• Development of therapeutic approaches to ‘triple negative’ phenotype breast cancer

  2008cites this paper
• Hypoxia-inducible factor (HIF)-1 alpha directly enhances the transcriptional activity of stem cell factor (SCF) in response to hypoxia and epidermal growth factor (EGF).

  2008cites this paper
• A phase II study of imatinib mesylate and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338.

  2008cites this paper
• Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy

  2008cites this paper
• Basal-like breast cancer: a critical review.

  2008cites this paper
• Lack of c-kit receptor promotes mammary tumors in N-nitrosomethylurea-treated Ws/Ws rats

  2008cites this paper
• Expression and Mutation Analysis of the Tyrosine Kinase c-Kit in Poorly Differentiated and Anaplastic Thyroid Carcinoma

  2008cites this paper
• Molecular Subtypes in Breast Cancer Evaluation and Management: Divide and Conquer

  2008cites this paper
• Impact of Basal-Like Breast Carcinoma Determination for a More Specific Therapy

  2008cites this paper
• Expression of c-kit proto-oncogene product in breast cancer tissues

  2007cites this paper
• c-KIT expression in columnar cell lesions of the breast accompanied by benign and malignant breast diseases.

  2007cites this paper
• The importance of c-Kit and PDGF receptors as potential targets for molecular therapy in breast cancer.

  2007cites this paper
• Triple negative tumours: a critical review

  2007cites this paper
• [Expression of c-kit in North African nasopharyngeal carcinomas: correlation with age and LMP1].

  2007cites this paper
• Positive immunohistochemical staining of KIT in solid-pseudopapillary neoplasms of the pancreas is not associated with KIT/PDGFRA mutations

  2006cites this paper
• C-kit gene mutation: common and widely distributed in intracranial germinomas.

  2006cites this paper
• C-KIT expression in ductal carcinoma in situ of the breast: co-expression with HER-2/neu.

  2006cites this paper
• Basoluminal Carcinoma: A New Biologically and Prognostically Distinct Entity Between Basal and Luminal Breast Cancer

  2006cites this paper
• Proteomics of Breast Cancer

  2006cites this paper
• A loss of c-kit expression is associated with an advanced stage and poor prognosis in breast cancer

  2006influential citation
• Kit expression in spindle cell rhabdomyosarcoma can possibly create a different approach for its tumorigenesis and therapy.

  2006cites this paper
• KIT is highly expressed in adenoid cystic carcinoma of the breast, a basal-like carcinoma associated with a favorable outcome

  2005cites this paper
• Overexpression of h-prune in breast cancer is correlated with advanced disease status.

  2005influential citation
• KIT (CD117): A Review on Expression in Normal and Neoplastic Tissues, and Mutations and Their Clinicopathologic Correlation

  2005cites this paper
• Expression of c-kit in adenoid cystic carcinoma of the breast.

  2005cites this paper
• A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer

  2005cites this paper